Cargando…

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors

Here, we applied optoRAF, an optogenetic tool for light-controlled clustering and activation of RAF proteins that mimics the natural occurring RAS-mediated dimerization. This versatile tool allows studying the effect on BRAF and CRAF homodimer- as well as heterodimer-induced RAF signaling. Vemurafen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatelle, Claire V., Hövermann, Désirée, Müller, Anne, Wagner, Hanna J., Weber, Wilfried, Radziwill, Gerald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812324/ https://www.ncbi.nlm.nih.gov/pubmed/27025703 http://dx.doi.org/10.1038/srep23713

Ejemplares similares

Optogenetic clustering of CNK1 reveals mechanistic insights in RAF and AKT signalling controlling cell fate decisions
por: Fischer, Adrian, et al.
Publicado: (2016)

Three distinct regions of cRaf kinase domain interact with membrane
por: Prakash, Priyanka, et al.
Publicado: (2019)

Optogenetic Approaches for the Spatiotemporal Control of Signal Transduction Pathways
por: Kramer, Markus M., et al.
Publicado: (2021)

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
por: Heidorn, Sonja J., et al.
Publicado: (2010)

The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho–Ser-621 in the C terminus of CRAF
por: Yuan, Jimin, et al.
Publicado: (2018)

X-linked Inhibitor of Apoptosis Protein negatively regulates neuronal differentiation through interaction with cRAF and Trk
por: Fadó, Rut, et al.
Publicado: (2013)

Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
por: Bhargava, Ajay, et al.
Publicado: (2016)

Optogenetic control of integrin-matrix interaction
por: Baaske, Julia, et al.
Publicado: (2019)

Cell Cycle Control by Optogenetically Regulated Cell Cycle Inhibitor Protein p21
por: Lataster, Levin, et al.
Publicado: (2023)

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
por: Jaiswal, Bijay S., et al.
Publicado: (2009)

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition
por: Noeparast, Amir, et al.
Publicado: (2019)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Interactome dynamics of RAF1-BRAF kinase monomers and dimers
por: Iglesias-Martinez, Luis F., et al.
Publicado: (2023)

Sex disparities in non-small cell lung cancer: mechanistic insights from a cRaf transgenic disease model
por: Zhong, Shen, et al.
Publicado: (2023)

A CRAF/glutathione-S-transferase P1 complex sustains autocrine growth of cancers with KRAS and BRAF mutations
por: Niitsu, Yoshiro, et al.
Publicado: (2020)

Direct and Indirect Control of Mitogen-activated Protein Kinase Pathway-associated Components, BRAP/IMP E3 Ubiquitin Ligase and CRAF/RAF1 Kinase, by the Deubiquitylating Enzyme USP15
por: Hayes, Sebastian D., et al.
Publicado: (2012)

Selective CRAF Inhibition Elicits Transactivation
por: Morgan, Charles W., et al.
Publicado: (2021)

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2
por: Advani, Sunil J., et al.
Publicado: (2015)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

Membrane localization of acetylated CNK1 mediates a positive feedback on RAF/ERK signaling
por: Fischer, Adrian, et al.
Publicado: (2017)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma
por: Luan, Zhou, et al.
Publicado: (2014)

RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
por: Zebisch, Armin, et al.
Publicado: (2019)

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
por: Pan, Jing-hua, et al.
Publicado: (2018)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
por: Bollag, Gideon, et al.
Publicado: (2010)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014)

Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
por: Tkacik, Emre, et al.
Publicado: (2023)

Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo
por: Clerk, Angela, et al.
Publicado: (2022)

A MEK-independent role for CRAF in mitosis and tumor progression
por: Mielgo, Ainhoa, et al.
Publicado: (2011)

CRAF R391W is a melanoma driver oncogene
por: Atefi, Mohammad, et al.
Publicado: (2016)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2015)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2017)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Production, Purification and Characterization of Recombinant Biotinylated Phytochrome B for Extracellular Optogenetics
por: Hörner, Maximilian, et al.
Publicado: (2020)

Targeting the Raf kinases in human cancer: the Raf dimer dilemma
por: Durrant, David E, et al.
Publicado: (2018)

Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
por: Holderfield, M, et al.
Publicado: (2014)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer
por: Noeparast, Amir, et al.
Publicado: (2018)

Impaired neuronal maturation of hippocampal neural progenitor cells in mice lacking CRAF
por: Pfeiffer, Verena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u090kvu85pa228msm45alcn7qn